Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3 Trial, Randomized, Open-Label, of NOV-002 in Combination With Paclitaxel and Carboplatin vs. Paclitaxel and Carboplatin Alone for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)

NCT00347412 is registered in ClinicalTrials.gov with Cellectar Biosciences, Inc. as lead sponsor.

NCT NCT00347412
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00347412 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3 Trial, Randomized, Open-Label, of NOV-002 in Combination With Paclitaxel and Carboplatin vs. Paclitaxel and Carboplatin Alone for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
Lead sponsor
Cellectar Biosciences, Inc.
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2006
Completion date
February 28, 2010
Enrollment
903 (actual)
Sites
75

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer